Geopolitical
MEDIUMTrigger: Chinese competition
Monitor: geopolitical
SMS Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +32.3%Average12w StreakAccelerating
In , SMS Pharmaceuticals Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +32.3% relative strength. Fundamentals: Average. On a 12-week streak.
SMS Pharmaceuticals Ltd Key Facts
- PE Ratio
- 43.5x
- Price/Book
- 4.08x
- Market Cap
- ₹3,899 Cr
- PAT Growth YoY
- +28%
- Revenue Growth YoY
- +21%
- OPM
- 21.0%
- RS vs Nifty 500
- +32.3%
PE: At PeakRiding Wave
What's Happening
📊PE near cycle highs — limited room for further expansion
👔Promoter buying — stake up 3.4% this quarter
💰Trading 60% above estimated fair value — significant premium
Key Risks
1. Geopolitical
MEDIUM2. Commodity
MEDIUMKey Numbers
PAT Growth YoY
+28%
Stable
Revenue YoY
+21%
Stable
Operating Margin
21.0%
+200 bps YoY
PE Ratio
43.5
PEG Ratio
5.60
EV/EBITDA
19.9
Current Price
₹416
Dividend Yield
0.10%
Fundamental Score
40/100
Average
3Y PAT CAGR
+4%
Market Cap
3.9K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Are the Key Risks for SMS Pharmaceuticals Ltd?
Earnings deceleration risks from management commentary
Commodity
MEDIUMTrigger: raw material volatility
Monitor: commodity
What Is SMS Pharmaceuticals Ltd's Management Saying?
Key quotes from recent conference calls
“faces headwinds from raw material volatility and Chinese competition [Risk (geopolitical): MEDIUM]”
“faces headwinds from raw material volatility [Risk (commodity): MEDIUM]”
How Fast Is SMS Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +21% | +15% | Stable |
| PAT (Net Profit) | +28% | +4% | Stable |
| OPM | 21.0% | +200 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: SMS Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were SMS Pharmaceuticals Ltd's latest quarterly results?
SMS Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +27.8% (stable)
- Revenue Growth YoY: +21.4%
- Operating Margin: 21.0% (volatile)
Is SMS Pharmaceuticals Ltd's profit growing or declining?
SMS Pharmaceuticals Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +27.8% (latest quarter)
- PAT Growth QoQ: -8.0% (sequential)
- 3-Year PAT CAGR: +3.6%
- Trend: Stable — consistent growth pattern
What is SMS Pharmaceuticals Ltd's revenue growth trend?
SMS Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +21.4%
- Revenue Growth QoQ: -13.2% (sequential)
- 3-Year Revenue CAGR: +14.6%
How is SMS Pharmaceuticals Ltd's operating margin trending?
SMS Pharmaceuticals Ltd's operating margin is volatile.
- Current OPM: 21.0%
- OPM Change YoY: +2.0% basis points
- OPM Change QoQ: +1.0% basis points
What is SMS Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
SMS Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: +3.6%
- 3-Year Revenue CAGR: +14.6%
Is SMS Pharmaceuticals Ltd's growth accelerating or decelerating?
SMS Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -50.8% bps
- Sequential Acceleration: -33.0% bps
What is SMS Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
SMS Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹88 Cr
- TTM PAT Growth: +35.4% YoY
- TTM Revenue: ₹896 Cr
- TTM Revenue Growth: +14.9% YoY
- TTM Operating Margin: 19.1%
Is SMS Pharmaceuticals Ltd overvalued or undervalued?
SMS Pharmaceuticals Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 43.5x
- Price-to-Book: 5.3x
What is SMS Pharmaceuticals Ltd's current PE ratio?
SMS Pharmaceuticals Ltd's current PE ratio is 43.5x.
- Current PE: 43.5x
- Market Cap: 3.9K Cr
- Dividend Yield: 0.10%
How does SMS Pharmaceuticals Ltd's valuation compare to its history?
SMS Pharmaceuticals Ltd's current PE is 43.5x.
- Current PE: 43.5x
- Valuation Assessment: Significantly Overvalued
What is SMS Pharmaceuticals Ltd's price-to-book ratio?
SMS Pharmaceuticals Ltd's price-to-book ratio is 5.3x.
- Price-to-Book (P/B): 5.3x
- Book Value per Share: ₹78
- Current Price: ₹416
Is SMS Pharmaceuticals Ltd a fundamentally strong company?
SMS Pharmaceuticals Ltd is rated Average with a fundamental score of 40.2/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +21.4% (10% weight)
- PAT Growth YoY: +27.8% (10% weight)
- PAT Growth QoQ: -8.0% (10% weight)
- Margins stable (10% weight)
- PEG Ratio: 5.6x vs sector median (15% weight)
- EV/EBITDA: 19.9x vs sector median (15% weight)
Is SMS Pharmaceuticals Ltd debt free?
SMS Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹324 Cr
What is SMS Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
SMS Pharmaceuticals Ltd's return ratios over recent years
- FY2023: ROCE 4.0%
- FY2024: ROCE 12.0%
- FY2025: ROCE 13.0%
Is SMS Pharmaceuticals Ltd's cash flow positive?
SMS Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹82 Cr
- Free Cash Flow (FCF): ₹-41 Cr
- CFO/PAT Ratio: 119% (strong cash conversion)
What is SMS Pharmaceuticals Ltd's dividend yield?
SMS Pharmaceuticals Ltd's current dividend yield is 0.10%.
- Dividend Yield: 0.10%
- Current Price: ₹416
Who holds SMS Pharmaceuticals Ltd shares — promoters, FII, DII?
SMS Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 68.1%
- FII (Foreign): 0.3%
- DII (Domestic): 3.0%
- Public: 28.6%
Is promoter holding increasing or decreasing in SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 68.1% (Mar 2026)
- Previous Quarter: 68.1% (Dec 2025)
- Change: 0.00% (stable)
How long has SMS Pharmaceuticals Ltd been outperforming Nifty 500?
SMS Pharmaceuticals Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Is SMS Pharmaceuticals Ltd a new momentum entry or an established outperformer?
SMS Pharmaceuticals Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
What are the key risks in SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd has 2 key risks worth monitoring
- [MEDIUM] Geopolitical — Chinese competition
- [MEDIUM] Commodity — raw material volatility
What did SMS Pharmaceuticals Ltd's management say in the latest earnings call?
In Sep 2025, SMS Pharmaceuticals Ltd's management highlighted
- "faces headwinds from raw material volatility and Chinese competition [Risk (geopolitical): MEDIUM]"
- "faces headwinds from raw material volatility [Risk (commodity): MEDIUM]"
Is SMS Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why SMS Pharmaceuticals Ltd may be worth studying
- Earnings growing at +27.8% YoY
- Cash flow is positive — CFO ₹82 Cr
What is the investment thesis for SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +21.4% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
- Key risk: Geopolitical
What is the future outlook for SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
- Key Risk: Geopolitical
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.